ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1095

Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience

Khalil Bourji1, Christopher Mecoli2, Julie Paik3, Jemima Albayda3, Eleni Tiniakou3, William Kelly3, Thomas E Lloyd3, Andrew Mammen4 and Lisa Christopher-Stine3, 1Wayne State University/Henry Ford Hospital, Dearborn, MI, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4NIH, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: Myositis, Work Force

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the prevalence of avascular necrosis (AVN) in a large cohort of patients with idiopathic inflammatory myopathies (IIM) and define the major associated risk factors.

Methods: We retrospectively reviewed the electronic medical records of all patients with a definitive diagnosis of IIM in our cohort, querying for keywords (“avascular necrosis”, “AVN”, “osteonecrosis”). Pertinent demographic, clinical (including major risk factors for AVN), serologic and imaging data were collected. A matched group of patients without AVN was then selected for comparison (matched for sex, age at IIM diagnosis ± 2 years, and duration of IIM ± 1 year).

Results: A total of 1680 patients were diagnosed with IIM between 2003 and 2017. Fifty-three patients developed AVN, with a global prevalence of 3.1% (53/1680). Musculoskeletal magnetic resonance imaging (MSK MRI) was available for 1085 patients and AVN was present in 48 patients, with a relative prevalence of 4.4% (48/1085). The majority of patients were Caucasian females (57%) with a mean age at diagnosis of 44.512.4 years. 59% had dermatomyositis (DM), 28% had polymyositis (PM). The median time from diagnosis of IIM to diagnosis of AVN was 46 months. Only 18 % were symptomatic. Hip joint was involved in 77%, Knee joint in 16% and Shoulder joint in 7%. A history of alcohol use was the only risk factor that was statistically associated with AVN (36% vs 13%; OR=3.98, CI [1.31-12.0], p=0.01). Corticosteroid use was not associated with an increased risk of AVN.

Conclusion: Although mostly asymptomatic, the global prevalence of AVN in IIM was 3.1% but the prevalence on MSK MRI was 4.4% and alcohol use was the only risk factor for AVN development.


Disclosure: K. Bourji, None; C. Mecoli, None; J. Paik, None; J. Albayda, None; E. Tiniakou, None; W. Kelly, None; T. Lloyd, None; A. Mammen, None; L. Christopher-Stine, None.

To cite this abstract in AMA style:

Bourji K, Mecoli C, Paik J, Albayda J, Tiniakou E, Kelly W, Lloyd T, Mammen A, Christopher-Stine L. Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/avascular-necrosis-in-the-hopkins-myositis-cohort-a-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/avascular-necrosis-in-the-hopkins-myositis-cohort-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology